AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02205853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The multi-faceted (MF) strategy
Description: The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
Study NCT03997682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands-Up Program
Description: In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
Study NCT05289258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological treatment
Description: combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
Study NCT05289258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
Description: This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
Study NCT05289258 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist group
Description: The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
Study NCT05773313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Open Table
Description: An organization that connects community volunteers to individuals in need to help overcome life's challenges.
Study NCT06426823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline / placebo
Description: NaCl (9 mg/ml)
Study NCT06426823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline / placebo
Description: NaCl (9 mg/ml)
Study NCT06426823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: GIP(3-30)NH2
Study NCT06480942 — intervention group
Intervention type: OTHER
Intervention: Detection of preload responders by a PLR test
Description: Detection of preload dependency by using PLR test and echocardiography
Study NCT04763044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT04763044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT04763044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT04763044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT04763044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm SnF2
Description: Each subject will be assigned to this treatment during the fifth period for this crossover study.
Study NCT04958122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime 400mg
Description: Oral cefixime 400 mg, one capsule, twice a day for 10 days
Study NCT04958122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzathine penicillin
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study NCT04339920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spermine Measuring Device
Description: The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
Study NCT05843110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision-making process
Description: Retrospective evaluation using scales, questionnaires and a semi-structured interview
Study NCT06169735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
Study NCT06169735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Portable Handheld Imaging
Description: Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
Study NCT05253612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Analog testing conducted by a trained test leader using, ISPOCD test battery
Description: Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
Study NCT05253612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: self-administered Mindmore digital cognitive screening battery
Description: Cognitive function will be measured by using the Mindmores digital test battery
Study NCT05032534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cone Small, Qufora A/S
Description: Newly developed cone in a softer material and a design matching the use for transanal irrigation.
Study NCT05032534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colotip, Coloplast A/S
Description: Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
Study NCT05157022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock-wave Therapy
Study NCT05157022 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock-wave Therapy
Study NCT05956613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial pulpotomy
Description: Use of newly introduced bioceramic putty in partial pulpotomy
Study NCT05669170 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial intervention
Description: The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours.
Study NCT05669170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours.
Study NCT05669170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: norepinephrine and dopamine reuptake inhibitor
Study NCT05377567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + FIBRO-On
Description: Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
Study NCT05377567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + FIBRO-Out
Description: Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
Study NCT05377567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT06097793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-101
Description: Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study NCT05315622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
Description: Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
Study NCT05315622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manual tension without reaching the manipulation thrust
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Appearance Distress
Description: Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face.
Study NCT05419245 — intervention group
Intervention type: OTHER
Intervention: FACE-Q | Craniofacial - Facial Function
Description: Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning.
Study NCT06529432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
Study NCT06529432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride Injection
Description: Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
Study NCT05242445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
Study NCT05101369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
Study NCT04798235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSHA-101
Description: AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
Study NCT05154058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Subperiosteal Release with Sharp Dissection
Description: Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
Study NCT05154058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Subperiosteal Release with Electrocautery
Description: Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
Study NCT06527885 — intervention group
Intervention type: DRUG
Intervention: Lurasidone
Description: Patients treated with Lurasidone in according to routine clinical practice, in Italy
Study NCT06469983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ErigoBasic or ErigoPro®
Description: Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
Study NCT06469983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Verticalization
Description: gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
Study NCT05857397 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study NCT06078826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive music therapy
Description: 30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
Study NCT06078826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
Study NCT05242445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection or as an IV infusion.
Study NCT04979949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study NCT04979949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Turkovac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study NCT04981574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching on neck area and thoracic thrust manipulation
Description: 1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times.
Study NCT05531708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin CAR-T cells
Description: D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
Study NCT05531708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
Study NCT05531708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
Study NCT05236400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)
Description: Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
Study NCT05236400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual phlegm suction system
Description: Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
Study NCT04723394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Study NCT04723394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Study NCT05906940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
Study NCT06194006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up
Description: Follow-up grafted patients as long as their condition allows